title: Mycophenolate sodium for immunosuppressive treatment in uveitis.
abstract: OBJECTIVE
  To assess the efficacy and tolerability of mycophenolate sodium (MPS) in patients with uveitis.
  
  
  METHODS
  Retrospective analysis including uveitis patients treated with MPS (Myfortic) for at least 3 months duration. MPS was administered in a dose of 720 mg twice daily.
  
  
  RESULTS
  We analyzed 35 patients (65 affected eyes) with anterior (n = 5), intermediate (n = 23), posterior (n = 6), and panuveitis (n = 1). Previous treatment consisted of systemic corticosteroids in all patients and at least one immunomodulating agent in 15 patients. Mean duration of MPS therapy was calculated as 9.6 months (3-31 months). MPS was able to control intraocular inflammation without relapse in 30 patients (85.7%). Stabilization or improvement of visual acuity was achieved in 60 eyes (92.3%). Tolerability of MPS was good or moderate in 34 patients (97.1%).
  
  
  CONCLUSIONS
  MPS was demonstrated as an effective and well-tolerated immunosuppressive drug for different forms of uveitis.
authors.affiliation: Centre for Ophthalmology, University of Tübingen, Tübingen, Germany. christoph.deuter@med.uni-tuebingen.de
authors.forename: Christoph M E
authors.initials: CM
authors.lastname: Deuter
authors.forename: Deshka
authors.initials: D
authors.lastname: Doycheva
authors.forename: Nicole
authors.initials: N
authors.lastname: Stuebiger
authors.forename: Manfred
authors.initials: M
authors.lastname: Zierhut
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D019233:Retreatment; D012189:Retrospective Studies; D017211:Treatment Failure; D016896:Treatment Outcome; D014605:Uveitis / Q000188:drug therapy* / Q000503:physiopathology; D014792:Visual Acuity / Q000187:drug effects; D055815:Young Adult
chemical_list: D000305:Adrenal Cortex Hormones; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid